ClinicalTrials.gg
CompletedNCT02979639Updated Oct 8, 2019Results posted

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

A Phase 3 interventional study of GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 11 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-08.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
404
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
19th of 46
404 · median 239
Started
2017
the only one that year
Phase 3
22 of 46
2 open now
Registered
20th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 19th largest by enrollment, is the only one that started in 2017, is one of 22 in phase 3, and was the 20th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the impact of reactogenicity of GSK Biologicals' HZ/su vaccine on Quality of Life (QoL) in adults ≥ 50 years of age

Read the detailed description

The study will evaluate the impact of HZ/su vaccination on the QoL, 400 adults ≥ 50 years of age (YOA). Subjects will be asked to respond to a series of SF-36 and EQ-5D questionnaires before and after vaccination following a 2 month schedule. To estimate the impact of reactogenicity on an individual's physical functioning (PF) and QoL, the study will compare subject questionnaire responses made during two periods, i.e., pre-vaccination and post-vaccination. The difference will be considered to be the effect of vaccination and reactogenicity on the PF and QoL. To characterize the study population and determine if frailty may influence reactogenicity and consequently the impact on QoL scores, the subjects' frailty status will be assessed at the first inclusion visit. In addition to the SF-36 and EQ-5D questionnaires, a more complete characterization of the reactogenicity of the vaccine will be made by including a detailed collection of the use of healthcare resources and the occurrence of symptoms through diary card data collection. Impact on days of work loss, both for the subject or for a caregiver, as applicable, will also be assessed.

Note that as a result of internal change in data standards terminology, the study data collected was converted to cDISC and the statistical analysis plan was amended accordingly. "Day 0" in the study design was replaced by "Day 1"; consequently, "Day n" was replaced by "Day n+1". Thus, the timeframes (Day 0, Day n) of Outcome Measures described in this study record are different to that denoted in the full protocol document posted.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Herpes Zoster
  • Reactogenicity
  • Quality of life
  • Shingles
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the questionnaires and diary cards).
  • Written obtained from the subject prior to performance of any study specific procedure.
  • A male or female aged ≥ 50 YOA at the time of consent.
  • Female subjects of non- may be enrolled in the study.

    • For this study population, non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Any condition which, in the judgment of the investigator, would make intramuscular (IM) injection unsafe.
  • Use or planned use of any or non-registered product (drug or vaccine) other than the study vaccine or current participation or planned concurrent participation in another clinical study, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device) during the period starting 30 days before the first dose of study vaccine and the study end.
  • Use or anticipated use of or other immune-modifying drugs during the period starting 180 days prior to study start and during the whole study period. This includes chronic administration of (> 14 consecutive days of prednisone at a dose of ≥ 20 mg/day [or equivalent]), long-acting immune-modifying agents (e.g., infliximab) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat disorders). Inhaled, topical and intra-articular corticosteroids are allowed.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., , [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders).
  • Administration of immunoglobulins and/or any blood products in the period starting 90 days preceding the first dose of study vaccine or planned administration during the study period.
  • Administration or planned administration of a in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine in the period starting 15 days prior to and ending 14 days after either dose of study vaccine.
  • Previous or planned administration of a vaccine against HZ (including an investigational or non-registered vaccine) other than the study vaccine, during the entire study period.
  • History of HZ.
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Female planning to become pregnant or planning to discontinue precautions.
  • Pregnant or lactating female.
  • Significant underlying illness requiring medications that might confound the evaluation of general/ local AEs, or in the opinion of the investigator, would be expected to prevent completion of the study.
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
404 participants (actual)

Study arms

  • Experimental
    GSK1437173A Group

    Subjects ≥ 50 years of age who will receive two doses of the GSK1437173A vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.

    Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

Interventions

  • BiologicalGSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

    Drug page: Shingrix

    2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.

06

What researchers measure

Primary outcomes

  1. Change in the Short Form 36-item-health Survey (SF36) Physical Functioning (PF) From Baseline Score to Mean Score After First Dose

    Descriptive analysis of the mean and standard deviation (SD) of the change from baseline of the SF-36 physical functioning (PF) score pre- and post dose 1 overall. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were Days 2 to 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

    Time frame: From Baseline at Day -7 to Day 8 after first dose

Secondary outcomes

  1. Change in Mean SF-36 PF Scale Scores From Baseline Score to Mean Score After Second Dose

    Descriptive analysis of the mean and standard deviation of the change from baseline of the SF-36 PF scale score pre and post dose 2 overall. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after second vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (Day 1 for dose 2). The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

    Time frame: From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)

  2. Change in Mean SF-36 PF Single Item Scores After First Dose

    Descriptive analysis of the change in mean SF-36 PF single item score from baseline. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after the first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were Days 2 to 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning. Among items are vigorous activities (running, lifting heavy objects, participating in strenuous sports), moderate activities (moving a table, pushing a vaccum cleaner, bowling, or playing golf) and others, described in the categories below.

    Time frame: From Baseline at Day -7 to Day 8 after first dose

  3. Change in Mean SF-36 PF Single Item Scores After Second Dose

    Descriptive analysis of the change in mean SF-36 PF single item score from baseline. Baseline versus mean score over the period Day 2 to Day 8 after each vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning. Among items are vigorous activities (running, lifting heavy objects, participating in strenuous sports), moderate activities (moving a table, pushing a vaccum cleaner, bowling, or playing golf) and others, described in the categories below.

    Time frame: From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)

  4. Change in SF-36 Role Physical Scores After First Dose

    Descriptive analysis. SF-36 Role physical scores change was measured from baseline score. Baseline versus mean score on Day 8 after first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

    Time frame: From Baseline at Day -7 to Day 8 after first dose

  5. Change in SF-36 Role Physical Scores After Second Dose

    Descriptive analysis. SF-36 Role Physical scores change was measured from baseline score. Changes in the score were measured as Baseline versus Day 8 score after the second vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

    Time frame: From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)

  6. Change in Quality-adjusted Life Year (QALY) After First Dose

    Descriptive analysis. QALY estimation is done from baseline score, based on EQ-5D questionnaires. Baseline versus combined score over the period Day 2 to Day 8 after each vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of EQ-5D questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The EQ-5D is a generic measure of health status that provides a simple description profile based on 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are used to generate the EQ-5D index utility score. The EQ-5D index utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome.

    Time frame: From Baseline at Day -7 to Day 8 after first dose

  7. Change in QALY After Second Dose

    Descriptive analysis. QALY estimation is done from baseline score, based on EQ-5D questionnaires. Baseline versus combined score over the period Day 2 to Day 8 after each vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 and EQ-5D questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The EQ-5D is a generic measure of health status that provides a simple description profile based on 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles (e.g. 1-no problem/no symptom) and profiles are subsequently converted to a continuous single index utility score (higher scores represent a better quality of life).

    Time frame: From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)

  8. Number of Reactogenicity-triggered Medically Attended Visits After First Dose

    Medical attention and health resource utilization triggered by frequency of reactogenicity events. Healthcare resources included staff involved in the following activities: telephone calls, visit to general practitioner, visit to specialist, visit to emergency room and hospitalizations.

    Time frame: From Day 1 to Day 7 after first dose

  9. Number of Reactogenicity-triggered Medically Attended Visits After Second Dose

    Medical attention and health resource utilization triggered by frequency of reactogenicity events. Healthcare resources included staff involved in the following activities: telephone calls, visit to general practitioner, visit to specialist, visit to emergency room and hospitalizations.

    Time frame: From Day 1 to Day 7 after second dose

  10. Days of Work Loss for Subjects After First Dose

    Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for subjects, expressed in days.

    Time frame: From Day 1 to Day 7 after first dose

  11. Days of Work Loss for Subjects After Second Dose

    Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for subjects, expressed in days.

    Time frame: From Day 1 to Day 7 after second dose

  12. Days of Work Loss for Non-dedicated Caregivers After First Dose

    Descriptive analysis. Estimation of work loss of non-dedicated caregivers expressed in days.Data was not reported for this outcome measure as there was no work loss among the non-dedicated caregivers

    Time frame: From Day 1 to Day 7 after first dose

  13. Days of Work Loss for Non-dedicated Caregivers After Second Dose

    Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for non-dedicated caregivers, expressed in days. Data was not reported for this outcome measure as there was no work loss among the non-dedicated caregivers

    Time frame: From Day 1 to Day 7 after second dose

  14. Days of Extra Work for Dedicated Caregivers After First Dose

    Descriptive analysis. Estimation of extra work for dedicated caregivers. Data was not reported for this outcome measure as there was no extra work for the dedicated caregivers

    Time frame: From Day 1 to Day 7 after first dose

  15. Days of Extra Work for Dedicated Caregivers After Second Dose

    Descriptive analysis. Estimation of extra work for dedicated caregivers, expressed in days. Data was not reported for this outcome measure as there was no extra work for the dedicated caregivers

    Time frame: From Day 1 to Day 7 after second dose

  16. Number of Subjects With Any and Grade 3 Solicited Local Symptoms After First Dose

    Assessed solicited local symptoms were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 erythema/swelling =erythema/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: During a 7-day follow-up period (Day 1 to Day 7) after first dose.

  17. Number of Subjects With Any and Grade 3 Solicited Local Symptoms After Second Dose

    Assessed solicited local symptoms were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 erythema/swelling=erythema/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: During a 7-day follow-up period (Day 1 to Day 7) after second dose.

  18. Number of Days With Solicited Local Symptoms After First Dose

    Assessed solicited local symptoms were pain, erythema and swelling.

    Time frame: During a 7-day follow-up period (Day 1 to Day 7) after first dose.

  19. Number of Days With Solicited Local Symptoms After Second Dose

    Assessed solicited local symptoms were pain, erythema and swelling.

    Time frame: During a 7-day follow-up period (Day 1 to Day 7) after second dose.

  20. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms After First Dose

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal everyday activities. Grade 3 temperature=temperature≥39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: During a 7-day follow-up period (Day 1 to Day 7) after first dose.

  21. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms After Second Dose

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary, tympanic temperature ≥ 37.5 °C\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature≥39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: During a 7-day follow-up period (Day 1 to Day 7) after second dose.

  22. Number of Days With Solicited General Symptoms After First Dose

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\].

    Time frame: During a 7-day follow-up period (Day 1 to Day 7) after first dose.

  23. Number of Days With Solicited General Symptoms After Second Dose

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\].

    Time frame: During a 7-day follow-up period (Day 1 to Day 7) after second dose.

  24. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: During a 30-day follow-up period (Day 1 to Day 30) after any vaccination (across doses).

  25. Number of Subjects With Any and Related Serious Adverse Events (SAEs) During the Entire Study Period

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

    Time frame: From Day 1 to study end at Month 14

  26. Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From Day 1 to study end at Month 14

07

Results

Posted Oct 16, 2018

Participant flow

Participant flow — Overall Study
MilestoneGSK1437173A Group
Started401
Completed387
Not completed14
Withdrew: Withdrawal based on medical judgement1
Withdrew: Lost to follow-up8
Withdrew: Withdrawal by subject3
Withdrew: Adverse event2

Outcome measures

PrimaryChange in the Short Form 36-item-health Survey (SF36) Physical Functioning (PF) From Baseline Score to Mean Score After First Dose

Descriptive analysis of the mean and standard deviation (SD) of the change from baseline of the SF-36 physical functioning (PF) score pre- and post dose 1 overall. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were Days 2 to 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

Time frame:
From Baseline at Day -7 to Day 8 after first dose
Reported as:
Mean · Score units
Change in the Short Form 36-item-health Survey (SF36) Physical Functioning (PF) From Baseline Score to Mean Score After First Dose
Score unitsGSK1437173A Group
Change in the Short Form 36-item-health Survey (SF36) Physical Functioning (PF) From Baseline Score to Mean Score After First Dose1.9 ± 10.44
SecondaryChange in Mean SF-36 PF Scale Scores From Baseline Score to Mean Score After Second Dose

Descriptive analysis of the mean and standard deviation of the change from baseline of the SF-36 PF scale score pre and post dose 2 overall. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after second vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (Day 1 for dose 2). The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

Time frame:
From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)
Reported as:
Mean · Score units
Change in Mean SF-36 PF Scale Scores From Baseline Score to Mean Score After Second Dose
Score unitsGSK1437173A Group
Change in Mean SF-36 PF Scale Scores From Baseline Score to Mean Score After Second Dose-0.4 ± 10.38
SecondaryChange in Mean SF-36 PF Single Item Scores After First Dose

Descriptive analysis of the change in mean SF-36 PF single item score from baseline. Changes in the score were measured as Baseline versus mean score over the period Day 2 to Day 8 after the first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were Days 2 to 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning. Among items are vigorous activities (running, lifting heavy objects, participating in strenuous sports), moderate activities (moving a table, pushing a vaccum cleaner, bowling, or playing golf) and others, described in the categories below.

Time frame:
From Baseline at Day -7 to Day 8 after first dose
Reported as:
Mean · Score units
Change in Mean SF-36 PF Single Item Scores After First Dose
Score unitsGSK1437173A Group
Vigorous activites6.8 ± 26.26
Moderate activites1.5 ± 16.76
Lifting or carrying groceries1.5 ± 13.84
Climbing several flights0.7 ± 17.77
Climbing one flight0.5 ± 16.26
Bending, kneeling or stooping5.8 ± 19.86
Walking more than a mile-0.2 ± 19.28
Walking several hundred yards-0.1 ± 16.66
Walking one hundred yards1.8 ± 15.11
Bathing or dressing himself/herself0.9 ± 11.35
SecondaryChange in Mean SF-36 PF Single Item Scores After Second Dose

Descriptive analysis of the change in mean SF-36 PF single item score from baseline. Baseline versus mean score over the period Day 2 to Day 8 after each vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning. Among items are vigorous activities (running, lifting heavy objects, participating in strenuous sports), moderate activities (moving a table, pushing a vaccum cleaner, bowling, or playing golf) and others, described in the categories below.

Time frame:
From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)
Reported as:
Mean · Score units
Change in Mean SF-36 PF Single Item Scores After Second Dose
Score unitsGSK1437173A Group
Vigorous activities2.6 ± 22.58
Moderate activities-1.2 ± 16.82
Carrying groceries-0.2 ± 13.05
Climbing several flights-3.7 ± 18.76
Climbing one flight-1.6 ± 16.09
Bending or kneeling3.9 ± 19.32
Walking more than mile-2.3 ± 17.77
Walking several 100 yards-2.0 ± 15.30
Walking 100 Yards-0.1 ± 13.48
Bathing/dressing self1.0 ± 12.01
SecondaryChange in SF-36 Role Physical Scores After First Dose

Descriptive analysis. SF-36 Role physical scores change was measured from baseline score. Baseline versus mean score on Day 8 after first vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

Time frame:
From Baseline at Day -7 to Day 8 after first dose
Reported as:
Mean · Score units
Change in SF-36 Role Physical Scores After First Dose
Score unitsGSK1437173A Group
Change in SF-36 Role Physical Scores After First Dose1.4 ± 14.97
SecondaryChange in SF-36 Role Physical Scores After Second Dose

Descriptive analysis. SF-36 Role Physical scores change was measured from baseline score. Changes in the score were measured as Baseline versus Day 8 score after the second vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The SF-36 scale scores are constructed following the summated ratings of the questions and standardized SF-36 scoring algorithm. Scores range from 0 to 100, with a higher score representing a higher level of functioning.

Time frame:
From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)
Reported as:
Mean · Score units
Change in SF-36 Role Physical Scores After Second Dose
Score unitsGSK1437173A Group
Change in SF-36 Role Physical Scores After Second Dose-1.8 ± 16.40
SecondaryChange in Quality-adjusted Life Year (QALY) After First Dose

Descriptive analysis. QALY estimation is done from baseline score, based on EQ-5D questionnaires. Baseline versus combined score over the period Day 2 to Day 8 after each vaccination. Baseline for dose 1 is defined as the mean of the assessments at Day -7 and Day 1. The post-vaccination completion of EQ-5D questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The EQ-5D is a generic measure of health status that provides a simple description profile based on 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are used to generate the EQ-5D index utility score. The EQ-5D index utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome.

Time frame:
From Baseline at Day -7 to Day 8 after first dose
Reported as:
Mean · Score units
Change in Quality-adjusted Life Year (QALY) After First Dose
Score unitsGSK1437173A Group
Change in Quality-adjusted Life Year (QALY) After First Dose0.1829 ± 0.55551
SecondaryChange in QALY After Second Dose

Descriptive analysis. QALY estimation is done from baseline score, based on EQ-5D questionnaires. Baseline versus combined score over the period Day 2 to Day 8 after each vaccination. For dose 2 baseline is defined as the mean of the three assessments at Day -7, Day 1 and Day 61 (equivalent to Day 1 for dose 2) The post-vaccination completion of SF-36 and EQ-5D questionnaires brought home by the subjects were on Day 2 to Day 7, with Day 8 to be filled in at the site. The EQ-5D is a generic measure of health status that provides a simple description profile based on 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles (e.g. 1-no problem/no symptom) and profiles are subsequently converted to a continuous single index utility score (higher scores represent a better quality of life).

Time frame:
From Day -7 to first dose until Day 8 after second dose (equivalent to study Days -7 to 68)
Reported as:
Mean · Score units
Change in QALY After Second Dose
Score unitsGSK1437173A Group
Change in QALY After Second Dose0.1128 ± 0.52000
SecondaryNumber of Reactogenicity-triggered Medically Attended Visits After First Dose

Medical attention and health resource utilization triggered by frequency of reactogenicity events. Healthcare resources included staff involved in the following activities: telephone calls, visit to general practitioner, visit to specialist, visit to emergency room and hospitalizations.

Time frame:
From Day 1 to Day 7 after first dose
Reported as:
Number · Visits
Number of Reactogenicity-triggered Medically Attended Visits After First Dose
VisitsGSK1437173A Group
Attended by Telephone Call2
Attended by General Practicioner1
Attended by Specialist0
Attended by Emergency Room0
Attended by Hospitalization0
SecondaryNumber of Reactogenicity-triggered Medically Attended Visits After Second Dose

Medical attention and health resource utilization triggered by frequency of reactogenicity events. Healthcare resources included staff involved in the following activities: telephone calls, visit to general practitioner, visit to specialist, visit to emergency room and hospitalizations.

Time frame:
From Day 1 to Day 7 after second dose
Reported as:
Number · Visits
Number of Reactogenicity-triggered Medically Attended Visits After Second Dose
VisitsGSK1437173A Group
Attended by Telephone Call4
Attended by General Practitioner1
Attended by Specialist0
Attended by Emergency Room0
Attended by Hospitalization0
SecondaryDays of Work Loss for Subjects After First Dose

Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for subjects, expressed in days.

Time frame:
From Day 1 to Day 7 after first dose
Reported as:
Mean · Days
Days of Work Loss for Subjects After First Dose
DaysGSK1437173A Group
Days of Work Loss for Subjects After First Dose1.3 ± 1.0
SecondaryDays of Work Loss for Subjects After Second Dose

Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for subjects, expressed in days.

Time frame:
From Day 1 to Day 7 after second dose
Reported as:
Mean · Days
Days of Work Loss for Subjects After Second Dose
DaysGSK1437173A Group
Days of Work Loss for Subjects After Second Dose1.1 ± 0.4
SecondaryDays of Work Loss for Non-dedicated Caregivers After First Dose

Descriptive analysis. Estimation of work loss of non-dedicated caregivers expressed in days.Data was not reported for this outcome measure as there was no work loss among the non-dedicated caregivers

Time frame:
From Day 1 to Day 7 after first dose

No measurements were reported for this outcome.

SecondaryDays of Work Loss for Non-dedicated Caregivers After Second Dose

Descriptive analysis. Estimation of work loss due to any reaction related to the study vaccine for non-dedicated caregivers, expressed in days. Data was not reported for this outcome measure as there was no work loss among the non-dedicated caregivers

Time frame:
From Day 1 to Day 7 after second dose

No measurements were reported for this outcome.

SecondaryDays of Extra Work for Dedicated Caregivers After First Dose

Descriptive analysis. Estimation of extra work for dedicated caregivers. Data was not reported for this outcome measure as there was no extra work for the dedicated caregivers

Time frame:
From Day 1 to Day 7 after first dose

No measurements were reported for this outcome.

SecondaryDays of Extra Work for Dedicated Caregivers After Second Dose

Descriptive analysis. Estimation of extra work for dedicated caregivers, expressed in days. Data was not reported for this outcome measure as there was no extra work for the dedicated caregivers

Time frame:
From Day 1 to Day 7 after second dose

No measurements were reported for this outcome.

SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms After First Dose

Assessed solicited local symptoms were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 erythema/swelling =erythema/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
During a 7-day follow-up period (Day 1 to Day 7) after first dose.
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms After First Dose
ParticipantsGSK1437173A Group
Any Pain310
Grade 3 Pain16
Any Erythema92
Grade 3 Erythema6
Any Swelling53
Grade 3 swelling3
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms After Second Dose

Assessed solicited local symptoms were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 erythema/swelling=erythema/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
During a 7-day follow-up period (Day 1 to Day 7) after second dose.
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms After Second Dose
ParticipantsGSK1437173A Group
Any Erythema87
Grade 3 Erythema7
Any Pain292
Grade 3 Pain21
Any Swelling54
Grade 3 Swelling3
SecondaryNumber of Days With Solicited Local Symptoms After First Dose

Assessed solicited local symptoms were pain, erythema and swelling.

Time frame:
During a 7-day follow-up period (Day 1 to Day 7) after first dose.
Reported as:
Median · Days
Number of Days With Solicited Local Symptoms After First Dose
DaysGSK1437173A Group
Pain3 (2 to 4)
Erythema2 (2 to 4)
Swelling2 (2 to 4)
SecondaryNumber of Days With Solicited Local Symptoms After Second Dose

Assessed solicited local symptoms were pain, erythema and swelling.

Time frame:
During a 7-day follow-up period (Day 1 to Day 7) after second dose.
Reported as:
Median · Days
Number of Days With Solicited Local Symptoms After Second Dose
DaysGSK1437173A Group
Pain2.5 (2 to 3)
Erythema3.0 (2 to 4)
Swelling3.0 (1 to 4)
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms After First Dose

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal everyday activities. Grade 3 temperature=temperature≥39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
During a 7-day follow-up period (Day 1 to Day 7) after first dose.
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms After First Dose
ParticipantsGSK1437173A Group
Any Fatigue134
Grade 3 Fatigue13
Related Fatigue120
Any Gastrointestinal symptoms53
Grade 3 Gastrointestinal symptoms4
Related Gastrointestinal symptoms40
Any Headache113
Grade 3 Headache11
Related Headache98
Any Myalgia107
Grade 3 Myalgia8
Related Myalgia100
Any Shivering50
Grade 3 Shivering3
Related Shivering48
Any Temperature (oral route)37
Grade 3 Temperature(≥39.0 °C)0
Related Temperature34
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms After Second Dose

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary, tympanic temperature ≥ 37.5 °C\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature≥39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
During a 7-day follow-up period (Day 1 to Day 7) after second dose.
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms After Second Dose
ParticipantsGSK1437173A Group
Any Fatigue180
Grade 3 Fatigue27
Related Fatigue172
Any Gastrointestinal symptoms53
Grade 3 Gastrointestinal symptoms4
Related Gastrointestinal symptoms44
Any Headache146
Grade 3 Headache11
Related Headache127
Any Myalgia128
Grade 3 Myalgia16
Related Myalgia121
Any Shivering97
Grade 3 Shivering14
Related Shivering86
Any Temperature (oral route)69
Grade 3 Temperature(≥39.0 °C)1
Related Temperature64
SecondaryNumber of Days With Solicited General Symptoms After First Dose

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\].

Time frame:
During a 7-day follow-up period (Day 1 to Day 7) after first dose.
Reported as:
Median · Days
Number of Days With Solicited General Symptoms After First Dose
DaysGSK1437173A Group
Fatigue2 (1 to 3)
Gastrointestinal symptoms1 (1 to 3)
Headache2 (1 to 3)
Myalgia2 (1 to 3)
Shivering1 (1 to 2)
Temperature1 (1 to 2)
SecondaryNumber of Days With Solicited General Symptoms After Second Dose

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and temperature \[defined as oral, axillary or tympanic temperature equal to or above (≥)37.5 degrees Celsius (°C)\].

Time frame:
During a 7-day follow-up period (Day 1 to Day 7) after second dose.
Reported as:
Median · Days
Number of Days With Solicited General Symptoms After Second Dose
DaysGSK1437173A Group
Fatigue2.0 (1 to 3)
Gastrointestinal symptoms2.0 (1 to 3)
Headache1.5 (1 to 2)
Myalgia2.0 (1 to 3)
Shivering1.0 (1 to 2)
Temperature1.0 (1 to 1)
SecondaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
During a 30-day follow-up period (Day 1 to Day 30) after any vaccination (across doses).
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsGSK1437173A Group
Any unsolicited adverse event127
Grade 3 unsolicited adverse events25
Related unsolicited adverse events29
SecondaryNumber of Subjects With Any and Related Serious Adverse Events (SAEs) During the Entire Study Period

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

Time frame:
From Day 1 to study end at Month 14
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Serious Adverse Events (SAEs) During the Entire Study Period
ParticipantsGSK1437173A Group
Any SAEs14
Related SAEs0
SecondaryNumber of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From Day 1 to study end at Month 14
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)
ParticipantsGSK1437173A Group
Any pIMDs2
Related pIMDs0

Adverse events

Collected over Solicited local and general adverse events: Day 1 to 7 after each vaccination. Unsolicited adverse events: From Day 1-30 after each vaccination. SAEs: From Day 1 to study completion (month 14).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Group2/401 (0.5%)14/401 (3.5%)370/401 (92.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventGSK1437173A Group
Aortic valve stenosisCardiac disorders1/401
Atrial fibrillationCardiac disorders1/401
Atrioventricular block completeCardiac disorders1/401
CardiomyopathyCardiac disorders1/401
Coronary artery diseaseCardiac disorders1/401
Stress cardiomyopathyCardiac disorders1/401
ColitisGastrointestinal disorders1/401
Large intestine perforationGastrointestinal disorders1/401
DiverticulitisInfections and infestations1/401
PneumoniaInfections and infestations1/401
Most frequent other events
Showing 10 of 112
Most frequent other events
EventGSK1437173A Group
Injection site painGeneral disorders341/401
FatigueGeneral disorders227/401
HeadacheNervous system disorders189/401
MyalgiaMusculoskeletal and connective tissue disorders169/401
injection site erythemaGeneral disorders125/401
ChillsGeneral disorders115/401
Gastrointestinal disorderGastrointestinal disorders88/401
PyrexiaGeneral disorders88/401
Injection site swellingGeneral disorders78/401
NasopharyngithisInfections and infestations10/401

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A Group
Mean64.6 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A Group
Female235
Male166
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A Group
African Heritage/African American48
American Indian or Alaskan Native7
Asian - East Asian Heritage2
Asian - South East Asian Heritage1
Other4
White - Arabic / North African Heritage7
White - Caucasian / European Heritage332
08

Study locations

11 sites
  • GSK Investigational Site
    Oakland, California 94612, United States
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80906, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80922, United States
  • GSK Investigational Site
    Meridian, Idaho 83646, United States
  • GSK Investigational Site
    Kansas City, Missouri 64114, United States
  • GSK Investigational Site
    Durham, North Carolina 27705, United States
  • GSK Investigational Site
    Corvallis, Oregon 97330, United States
  • GSK Investigational Site
    Uniontown, Pennsylvania 15401, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Norfolk, Virginia 23507, United States
09

References and documents

Publications

  • Schmader KE, Levin MJ, Grupping K, Matthews S, Butuk D, Chen M, Idrissi ME, Fissette LA, Fogarty C, Hartley P, Klein NP, Nevarez M, Uusinarkaus K, Oostvogels L, Curran D. The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial. J Gerontol A Biol Sci Med Sci. 2019 Jul 12;74(8):1217-1224. doi: 10.1093/gerona/gly218. PubMed 30256905 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2017, 2 months.

Results were first posted in Oct 2018, 1 year 6 months after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 2 months is below that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2016
First posted
Dec 1, 2016
StartActual
Jan 16, 2017
Primary completionActual
Apr 12, 2017
CompletionActual
May 24, 2018
Results first posted
Oct 16, 2018
Last update
Oct 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02979639
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 1, 2016
Start date
Jan 16, 2017
Primary completion
Apr 12, 2017
Completion
May 24, 2018
Results posted
Oct 16, 2018
Last update
Oct 8, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion